You are looking at 111 - 120 of 2,754 items for

  • Refine by Content Type: Articles x
Clear All Modify Search

Even after decades of follow-up, kidneys transplanted after circulatory determination of death (DCD) show similar outcomes to kidneys donated after brain death (DBD), reports a study in Nephrology Dialysis Transplantation.

Of 1133 kidney transplants performed between 1985 and 2000 at the authors’ Swiss medical center, 122 used DCD grafts. The DCD kidney recipients—74 men and 48 women, median age 46 years—were matched one to one for sex, age, and transplant year to patients receiving DBD grafts during the same period. Outcomes were assessed through 2020.

At 35 years’ follow-up, median graft survival was almost identical between groups: 24.5

For older adults with type 2 diabetes, treatment with a sodium glucose cotransporter-2 inhibitor (SGLT2i) is associated with a lower risk of acute kidney injury (AKI), compared with other antidiabetic medications, according to a pre-proof paper in the American Journal of Kidney Diseases.

The population-based cohort study used Medicare fee-for-service data on more than 417,000 patients, aged 66 years or older, with type 2 diabetes. All enrolled patients had a newly filled prescription for an SGLT2i, a dipeptidyl peptidase 4 inhibitor (DPP-4i), or a glucagon-like peptide-1 receptor agonist (GLP-1RA) from 2013 through 2017. New SGLT2i users were propensity

Daniel Edmonston and Neha Pagidipati

The nomenclature shift from contrast-induced to contrast-associated acute kidney injury (CA-AKI) reflects a waning confidence in the nephrotoxicity of iodinated contrast. Despite early animal and observational data supporting this nephrotoxicity (1, 2), more appropriately controlled and matched studies have failed to demonstrate this link (36). In 2004, Mehran and colleagues (7) developed a risk score to predict CA-AKI in people undergoing percutaneous coronary intervention (PCI). In a recent study published in The Lancet (8), the investigators aimed to update this risk score to reflect more contemporary clinical practices.

Tracy Hampton

Although kidney transplantation is the optimal therapy after kidney failure for prolonging patient survival and improving quality of life, kidneys transplanted from deceased donors often do not function longer than 10 to 15 years. Therefore, many recipients must eventually receive a second transplant or undergo dialysis, with considerations such as the scarcity of donor organs and the immunological sensitization of transplant recipients factoring into decisions related to these options.

Because direct comparison of transplantation versus dialysis continuation through a randomized controlled trial is not feasible due to ethical, biological, and logistic reasons, investigators recently conducted a retrospective study that analyzed

Tod Ibrahim

Last year, ASN President Susan E. Quaggin, MD, FASN, and I alternated sending monthly email updates to ASN members. Drafting these updates helped us put individual activities—such as the society's commitment to justice, equity, diversity, and inclusion—into a broader context. This year, we’re excited to publish these updates as editorials in ASN Kidney News.

2022 marks Dr. Quaggin's 33rd year as a member of ASN. “Over this period, it has been amazing to witness the growth and impact of our programs, which are driving innovation and positive changes in education, research, and patient care,” she told me recently.

Anitha Vijayan

The COVID-19 pandemic and kidney involvement constitute an evolving story with various twists and turns, and we expect new challenges as we enter the third year of the pandemic. In spring and summer of 2020, COVID-19-associated acute kidney injury (AKI) was one of the biggest challenges in hospitals, as physicians and staff dealt with a surge of COVID-19 patients on the wards and in the intensive care units (ICUs). The incidence of COVID-19-associated AKI in ICUs ranged from 61% to 76% in the United States, with approximately 30% of ICU patients needing kidney replacement therapy (KRT) (1). Patients

Edgar V. Lerma and Michelle G.A. Lim

Diabetic kidney disease (DKD) has been in the forefront of industry publications during these challenging yet exciting times. With the advent of recognition of sodium glucose co-transporter 2 (SGLT2) inhibitors and their particular outcome benefits in patients with type 2 diabetes who are particularly prone to developing complications related to cardiovascular (CV) disease, there has been revitalization of our understanding of the mineralocorticoid receptor and the central role it plays in inflammation and fibrosis involving the kidneys.

A nonsteroidal mineralocorticoid antagonist—finerenone—was highlighted in several major randomized controlled trials (1, 2) that enrolled adult patients with chronic

Lin Wang and Eugene Lin

The flurry of kidney-related policies continues unabated, and 2022 brings to the fore another set of policy challenges and opportunities (Figure 1).

Policies to Watch in 2022

A new eGFR equation

In 2020, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a joint task force aimed at addressing the use of race in the estimated glomerular filtration rate (eGFR). In a highly anticipated recommendation, the task force published alternatives to using race, a social construct, in eGFR. The task force also tackled challenges for the nephrology community moving forward (1

Tiffany Truong, Matthew R. Sinclair, and Sam Kant

Medical education, like medicine itself, has evolved over time—from the days of professional guilds and apprenticeships to the establishment of structured postgraduate residency training to duty-hours’ restrictions, changes in licensing exams, and the growth of innovative educational resources (1). As the design of medical training changes, so too does the type of physician it produces. After all, medical education is not simply the acquisition of knowledge or even of skills and experiences but a process of shaping and the metamorphosis of the learner.

In a field like medicine, interwoven as it is with the science and humanity of

Kenar Jhaveri

The knowledge and understanding of hypertension (HTN) have always been cornerstones of nephrology, and over the last 3 decades, nephrologists have emerged at the forefront of HTN management. As we look back over the last few years, several major trials and findings have emerged, leading to some changes in our ways of thinking and practice. I’ll highlight the top 10 major findings and studies that are making an impact in HTN management. In 2022, we need to continue to take ownership of HTN as nephrologists.

10. Managing hyperkalemia when using anti-HTN agents. Chronic kidney disease (CKD) and HTN